BIIB — Biogen Inc. stock price and chart

BIIB

Biogen Inc.Stock · HealthcareS&P 500 Equal Weight 0.2% · Nasdaq Composite 0.06% · S&P 500 0.05% · Russell 1000 0.05% · US Stock Market 0.04% · Russell 3000 0.04% · MSCI World 0.03% · MSCI ACWI 0.03%

$217.10+0.78%

as of market close, Sep 11, 2026

☾ AH — —

PeersMRNALLYUNHJNJMRKABBV

Technical analysis2

Overlay lines0

Addendum charts0

Volume

20162019202120242026

150.0200.0250.0300.0350.0400.0020.0M40.0M$217.10

2026-09-11

Price$217.10

MA20$198.61

MA50$175.81

Vol4.1M

What would $1,000 invested in BIIB be worth today? →

BIIB returns: By year · By month · By week · Trailing

Key stats

Price data

Price: $217.10
Change YTD: +23.36%
Next earnings: Oct 29, 2026
Market cap: 32.1B2016-09 68.1B2026-09 32.1B-52.9% over the window
Enterprise value: 35.3B
Shares outstanding: 147.6M2016-03 219.1M2026-03 147.6M-32.6% over the window
52W low: $135.39
52W high: $225.80
From 52W high: -3.85%
From 52W low: +60.35%
52W range: 90%
Beta: 0.16

Volume

Rel volume: 1.13×
30D volume: 774K
30D $ vol: 164.8M

Fundamentals

Sales (ttm): 9.9B2016-03 10.9B2026-03 9.9B-9.1% over the window
Sales/share: $67.312016-03 $49.922026-03 $67.31+34.8% over the window
EPS (ttm): $9.302016-03 $16.282026-03 $9.30-42.9% over the window
FCF (ttm): 2.4B2016-03 3.5B2026-03 2.4B-31.4% over the window
FCF/share: $16.412016-03 $16.122026-03 $16.41+1.8% over the window
Book value/share: $126.332016-03 $47.142026-03 $126.33+168.0% over the window
Net margin: 13.81%2016-03 33.8%2026-03 13.8%-59.1% over the window
ROE: 7.36%2016-03 35.8%2026-03 7.4%-79.4% over the window
ROA: 4.65%2016-03 17.9%2026-03 4.7%-74.0% over the window
Debt / equity: 0.34×2016-03 0.632026-03 0.34-46.7% over the window
Current ratio: 3.062016-03 2.592026-03 3.06+18.2% over the window

Growth (CAGR, ttm) · 10Y

Sales: +1.23%2025-03-31 → 2026-03-319.8B → 9.9B (+1.2% total)-0.72%2022-12-31 → 2026-03-3110.2B → 9.9B (-2.3% total)-4.64%2021-03-31 → 2026-03-3112.6B → 9.9B (-21.2% total)-0.95%2016-03-31 → 2026-03-3110.9B → 9.9B (-9.1% total)
Net income: -7.26%2025-03-31 → 2026-03-311.5B → 1.4B (-7.3% total)-21.79%2022-12-31 → 2026-03-313B → 1.4B (-55.0% total)-14.55%2021-03-31 → 2026-03-313B → 1.4B (-54.4% total)-9.44%2016-03-31 → 2026-03-313.7B → 1.4B (-62.9% total)
FCF: -0.57%2025-03-31 → 2026-03-312.4B → 2.4B (-0.6% total)+19.24%2023-03-31 → 2026-03-311.4B → 2.4B (+69.6% total)-5.20%2021-03-31 → 2026-03-313.2B → 2.4B (-23.4% total)-3.69%2016-03-31 → 2026-03-313.5B → 2.4B (-31.4% total)
Shares: +0.76%2025-03-31 → 2026-03-31146.5M → 147.6M (+0.8% total)+0.66%2023-03-31 → 2026-03-31144.7M → 147.6M (+2.0% total)-0.39%2021-03-31 → 2026-03-31150.6M → 147.6M (-1.9% total)-3.87%2016-03-31 → 2026-03-31219.1M → 147.6M (-32.6% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: -8.21%2025-03-31 → 2026-03-31$10.13 → $9.30 (-8.2% total)-22.04%2022-12-31 → 2026-03-31$20.87 → $9.30 (-55.4% total)-13.37%2021-03-31 → 2026-03-31$19.06 → $9.30 (-51.2% total)-5.45%2016-03-31 → 2026-03-31$16.28 → $9.30 (-42.9% total)
Sales/share: +0.47%2025-03-31 → 2026-03-31$66.99 → $67.31 (+0.5% total)-1.38%2022-12-31 → 2026-03-31$70.41 → $67.31 (-4.4% total)-4.27%2021-03-31 → 2026-03-31$83.72 → $67.31 (-19.6% total)+3.03%2016-03-31 → 2026-03-31$49.92 → $67.31 (+34.8% total)
FCF/share: -1.31%2025-03-31 → 2026-03-31$16.63 → $16.41 (-1.3% total)+18.46%2023-03-31 → 2026-03-31$9.87 → $16.41 (+66.3% total)-4.83%2021-03-31 → 2026-03-31$21.01 → $16.41 (-21.9% total)+0.18%2016-03-31 → 2026-03-31$16.12 → $16.41 (+1.8% total)
Book value/share: +9.03%2025-03-31 → 2026-03-31$115.87 → $126.33 (+9.0% total)+9.84%2023-03-31 → 2026-03-31$95.32 → $126.33 (+32.5% total)+12.23%2021-03-31 → 2026-03-31$70.95 → $126.33 (+78.1% total)+10.36%2016-03-31 → 2026-03-31$47.14 → $126.33 (+168.0% total)
Price: +45.90%2025-09-11 → 2026-09-11$148.84 → $217.10 (+45.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-5.70%2023-09-11 → 2026-09-11$258.92 → $217.10 (-16.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-6.25%2021-09-10 → 2026-09-11$299.81 → $217.10 (-27.6% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-3.05%2016-09-09 → 2026-09-11$296.10 → $217.10 (-26.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +45.90%2025-09-11 → 2026-09-11$148.84 → $217.10 (+45.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-5.70%2023-09-11 → 2026-09-11$258.92 → $217.10 (-16.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-6.25%2021-09-10 → 2026-09-11$299.81 → $217.10 (-27.6% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-3.05%2016-09-09 → 2026-09-11$296.10 → $217.10 (-26.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 23.3×2016-09 17.532026-09 23.36+33.3% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 12.9×2016-09 12.542026-09 12.94+3.2% over the window
Fwd P/E: 12.8×
P/S (ttm)Market cap ÷ TTM revenue.: 3.2×2016-09 5.972026-09 3.23-45.9% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 1.7×2016-09 5.622026-09 1.72-69.4% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 13.2×2016-09 18.772026-09 13.23-29.5% over the window
EV/EBITDA (fy): 13.1×
EV/Sales (ttm): 3.6×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 7.56%2016-06 5.1%2026-03 9.0%+75.5% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-03-31) ÷ shares_at(2025-03-31) = 1 − 147.6M ÷ 146.5M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -0.76%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-0.76%) + dividends paid over that year ($0) ÷ market_cap_at(2025-03-31) ($20.1B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -0.76%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($32.1B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2016-06 7.3%2026-03 0.0%-100.0% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($32.1B). Same caveat as the cash buyback yield.: 0.00%2016-06 7.3%2026-03 0.0%-100.0% over the window

Vs own 10Y history

P/E: 81st
P/OI: 71st
P/S: 43rd
P/B: 19th
P/FCF: 53rd

Bar = where today’s multiple sits in BIIB’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · windows as of 2026-09-11

+0.78%

-3.30%

+3.94%

+8.57%

YTD

+23.36%

+52.23%

-35.30%

Financial statements

Open full BIIB financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	-8.44%	-0.65%
JNJ	Johnson & Johnson	+2.31%	-0.29%
ABBV	AbbVie Inc.	+3.36%	+0.83%
MRK	Merck & Co. Inc.	+8.28%	-0.54%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	-6.53%	-2.37%
TMO	Thermo Fisher Scientific Inc.	+1.13%	+1.10%
AMGN	Amgen Inc.	-8.80%	-1.34%
GILD	Gilead Sciences Inc.	+5.78%	-0.75%

Biogen Inc. (BIIB) trades at $217.10 with a live price and an interactive chart covering 34+ years of daily price history, plus key valuation metrics. ChartRow also publishes BIIB’s financial statements free — annual and quarterly income statement, balance sheet, and cash flow straight from SEC filings, with P/E and valuation history and dividend data. See full BIIB financial statements →

BIIB — Biogen Inc. price, chart and key statistics

Key stats

Price data

Volume

Fundamentals

Growth (CAGR, ttm) · 10Y

Per-share growth (CAGR, ttm) · 10Y

Valuation

Vs own 10Y history

Performance · price return · windows as of 2026-09-11

Financial statements

Related Healthcare